<DOC>
	<DOCNO>NCT00074867</DOCNO>
	<brief_summary>The purpose study determine whether CP-547,632 , oral VEGFR-2 tyrosine kinase inhibitor effective treatment epithelial ovarian cancer , primary peritoneal serous cancer , fallopian tube cancer patient fail first line platinum-based therapy persistent rise CA-125 .</brief_summary>
	<brief_title>Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian , Peritoneal , Fallopian Tube Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<criteria>Histologically proven epithelial ovarian cancer , primary peritoneal serous cancer , fallopian tube cancerRecurrent persistent elevate CA125 . For purpose study , elevate CA125 define value â‰¥40 U/ml two separate consecutive determination make â‰¥1 week apart . CA125 value obtain within 4 week abdominal surgery take account . No definitive disease clinical finding small volume disease ( &amp; # 163 ; 1cm spiral CT &amp; # 163 ; 2cm conventional CT clinical exam ) . No prior exposure mouse antibodies prior VEGF VEGF receptor target treatment antiangiogenicdirected , anticancer treatment include thalidomide . No prior consolidation therapy cytotoxic agent ovarian cancer . Continuation hormone replacement therapy permit . No requirement concomitant anticoagulant therapy . Administration low dose anticoagulant maintenance central venous access permitted.No chronic oral intravenous steroid use .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2006</verification_date>
</DOC>